We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS Eyes More Cuts to Offset Pargluva Problems
BMS Eyes More Cuts to Offset Pargluva Problems
December 13, 2005
Bristol-Myers Squibb (BMS) plans to cut costs by at least $500 million in 2007 as part of a strategy to improve earnings growth and offset anticipated losses from its recent setback in the development of its key investigational diabetes drug Pargluva.